MCRB — Seres Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$5.39
+$0.21 (+4.05%)
Seres Therapeutics Inc (MCRB) is a biotechnology company listed on NASDAQ. It is led by Eric D. Shaff M.B.A., based in 101 Cambridgepark Drive, Cambridge, MA, United States, 02140, with about 103 employees. Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Latest reported MCRB revenue for 2025-09-30 was $351.0K. Net income was $8.2M. MCRB currently screens at market cap $109.8M.
Use this MCRB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MCRB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MCRB SEC filings page. Lician reads the product cache first so this HTML stays unique to Seres Therapeutics Inc even when a live quote feed is slow.
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
MCRB Key Statistics
Market Cap
$109.77M
Volume
102,957
Previous Close
$4.66
Day Range
$4.67 – $5.15
EPS
$0.00
Revenue
$0.00
Net Income
$136.00K
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
103
MCRB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $126.33M | $7.13M | $144.93M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $136.00K | -$113.72M | -$250.16M | -$65.58M |
| EPS (Diluted) | $0.00 | -$0.89 | -$2.31 | -$0.72 |
Total Assets
$139.81M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$30.79M
Operating Cash Flow
-$148.61M
Free Cash Flow
$0.00
Seres Therapeutics Inc Company Information
- President, CEO & Director
- Eric D. Shaff M.B.A.
- Headquarters
- 101 Cambridgepark Drive, Cambridge, MA, United States, 02140
- Website
- www.serestherapeutics.com
- Phone
- 617 945 9626
- IPO / Founded
- 2015-06-26
- Sector
- Healthcare
- Industry
- Biotechnology